Imvax is dedicated to addressing the most intractable solid tumors with the highest unmet need. In addition to our lead indication, Imvax is targeting other solid tumors in this challenging group for which standard of care has provided only modest incremental advances in overall survival. Recognizing the unique characteristics of each solid tumor, we are developing treatment strategies tailored to each.